pst3 Antibody

What is pSTAT3 and why is it important as a research target?

pSTAT3 refers to the phosphorylated form of STAT3, specifically when phosphorylated at tyrosine 705 (Tyr705), which enables dimerization and nuclear translocation for gene expression regulation . This phosphorylation event represents a key activation mechanism in STAT3 signaling pathways, which are crucial for mediating cellular responses to cytokines and growth factors, particularly in immune responses and cell proliferation .

The importance of pSTAT3 as a research target stems from its central role in numerous physiological and pathological processes. Dysregulation of STAT3 signaling has been implicated in various diseases, including cancer, where persistent activation can lead to uncontrolled cell growth . In autoimmune conditions, STAT3 phosphorylation plays a critical role in regulating immune responses and cytokine production . Therefore, tracking pSTAT3 levels provides valuable insights into disease mechanisms and potential therapeutic interventions.

How does STAT3 phosphorylation relate to its functional activity?

STAT3 phosphorylation at Tyr705 directly correlates with its functional activation and represents a measurable indicator of pathway engagement. Once phosphorylated, STAT3 forms dimers and translocates to the nucleus, where it binds to specific DNA sequences to regulate gene expression . This nuclear translocation is a critical step in the signaling cascade and can be directly visualized using imaging flow cytometry techniques.

The functional relationship between phosphorylation and activity is demonstrated in studies where IL-21 stimulation leads to robust STAT3 phosphorylation followed by nuclear accumulation of pSTAT3 . When this phosphorylation is blocked (for example, by ATR-107 antibody treatment), STAT3 fails to translocate to the nucleus, as confirmed by the absence of overlap between pSTAT3 and nuclear staining in imaging studies . This direct correlation between phosphorylation status and subcellular localization makes pSTAT3 detection a reliable method for assessing STAT3 pathway activation in experimental settings.

What are the key differences between various commercial pSTAT3 antibodies?

Commercial pSTAT3 antibodies differ primarily in their specificity, sensitivity, applications, and conjugation options. For instance, the p-Stat3 Antibody (B-7) is a mouse monoclonal IgG2b kappa light chain antibody that specifically recognizes STAT3 phosphorylated at Tyr705 in mouse, rat, and human samples . This antibody has been validated for multiple applications including western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry, flow cytometry, and ELISA .

When selecting a pSTAT3 antibody, researchers should consider:

• Phosphorylation site specificity (Tyr705 vs. other phosphorylation sites)

• Species reactivity (human, mouse, rat, etc.)

• Validated applications (WB, IP, IF, IHC, FCM, ELISA)

• Conjugation options (non-conjugated, HRP, PE, FITC, Alexa Fluor® conjugates)

• Clone characteristics and performance in specific experimental conditions

Some antibodies are available in various conjugated forms to facilitate different detection methods. For example, p-Stat3 (B-7) antibody is available with agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and various Alexa Fluor® conjugates , providing flexibility for diverse experimental approaches.

How can I optimize Western blotting protocols for pSTAT3 detection?

Western blotting for pSTAT3 detection requires careful optimization of several parameters to ensure sensitive and specific results. Based on established protocols, the following methodological considerations are essential:

• Sample preparation: Cells should be lysed in appropriate buffers containing phosphatase inhibitors to prevent dephosphorylation of STAT3 during sample processing. After sonication, samples should be heated at 95°C to denature proteins before loading .

• Gel electrophoresis and transfer: Use 10% SDS-PAGE gels for optimal separation of proteins in the 70-100 kDa range where STAT3 (~92 kDa) migrates. Transfer efficiency can be enhanced using systems like the iBlot® Gel Transfer system onto nitrocellulose membranes .

• Blocking and antibody incubation: Block membranes with PBS + 5% non-fat milk powder for one hour, then rinse three times with PBS + 0.1% Tween-20 before incubating with primary antibodies (such as pSTAT3 Tyr705, Cat#: 9145s) at 1:1000 dilution in PBS + 5% BSA overnight at 4°C .

• Detection: For enhanced sensitivity, use HRP-conjugated secondary antibodies at 1:10,000 dilution with appropriate chemiluminescent substrates . Alternatively, directly conjugated antibodies like p-Stat3 (B-7) m-IgGκ BP-HRP bundles can streamline the detection process .

• Controls: Always include total STAT3 detection (using antibodies such as STAT3 Cat#: 9139s) alongside pSTAT3 to normalize phosphorylation signals and account for variations in total protein expression .

When troubleshooting weak signals, consider extending the primary antibody incubation time, increasing antibody concentration, or employing signal enhancement systems appropriate for phospho-protein detection.

What are the advantages of using flow cytometry for pSTAT3 analysis compared to other methods?

Flow cytometry offers several distinct advantages for pSTAT3 analysis, particularly in heterogeneous cell populations and clinical samples:

• Cellular resolution: Unlike Western blotting which provides population-averaged results, flow cytometry enables quantification of pSTAT3 levels in individual cells, allowing identification of responsive subpopulations within a heterogeneous sample .

• Multiparametric analysis: Flow cytometry permits simultaneous analysis of pSTAT3 along with cell surface markers and other intracellular proteins, enabling comprehensive characterization of signaling responses in specific cell types without the need for prior cell isolation .

• Minimal sample requirement: The technique can be performed on small volumes of whole blood (100 μl per condition), making it suitable for clinical applications and longitudinal studies .

• Quantitative analysis: Flow cytometry provides objective quantification of pSTAT3 levels based on fluorescence intensity, allowing for precise measurement of signaling responses and inhibition by therapeutic agents .

In practical applications, flow cytometric analysis has successfully quantified IL-21-induced STAT3 phosphorylation in CD4+ T cells within whole blood samples. When plotted against antibody concentrations (such as ATR-107), inhibition curves can be generated, yielding IC50 values (e.g., 1.45 ± 0.26 ng/ml, n = 6) that provide quantitative measures of inhibitor potency . Similar approaches can be applied to other cell types, such as CD19+ B cells, expanding the utility of this method .

How can imaging flow cytometry advance our understanding of pSTAT3 translocation?

Imaging flow cytometry represents a powerful approach for analyzing pSTAT3 nuclear translocation that combines the quantitative aspects of flow cytometry with the spatial resolution of microscopy:

• Subcellular localization: Unlike conventional flow cytometry, imaging flow cytometry captures images of individual cells, allowing visualization and quantification of pSTAT3 subcellular distribution, particularly its translocation from cytoplasm to nucleus following activation .

• Nuclear translocation quantification: By simultaneously staining with nuclear dyes (such as DAPI) and pSTAT3-specific antibodies, researchers can measure nuclear translocation using similarity scores that quantify the correlation between pixel values of DAPI and pSTAT3 images on a per-cell basis .

• High-throughput analysis: The technique permits analysis of thousands of cells, providing statistically robust data on translocation events while maintaining single-cell resolution .

In practical application, imaging flow cytometry has been used to demonstrate that IL-21 stimulation induces not only increased phosphorylation of STAT3 but also its nuclear translocation, as evidenced by the co-localization of pSTAT3 (red) with nuclear staining (green) . Pre-treatment with inhibitors like ATR-107 blocks both phosphorylation and subsequent nuclear translocation, preventing the overlap between pSTAT3 and nuclear signals . This approach provides mechanistic insights beyond simple phosphorylation status by linking biochemical modification to functional subcellular redistribution.

How can pSTAT3 be utilized as a pharmacodynamic biomarker in drug development?

pSTAT3 serves as an excellent pharmacodynamic biomarker in drug development due to its direct relationship to receptor activation and downstream signaling. Its utility is demonstrated in several key applications:

• Target engagement assessment: As a direct downstream signal of receptor activation (e.g., IL-21R), pSTAT3 levels provide quantitative measurement of how effectively drugs engage their molecular targets . For example, in the development of ATR-107 (an IL-21R antibody), pSTAT3 inhibition strongly correlated with receptor occupancy, validating it as a reliable biomarker for target engagement .

• Dose-response relationship determination: pSTAT3 assays enable generation of detailed dose-response curves for inhibitory compounds. In the case of ATR-107, phosphorylation of STAT3 in T cells was concentration-dependently inhibited, with an IC50 of 1.45 ± 0.26 ng/ml . This quantitative data informs dose selection for subsequent clinical studies.

• Mechanism of action characterization: pSTAT3 analysis reveals mechanistic insights into drug action. For ATR-107, the observation that high doses of IL-21 could not overcome the inhibitory effect of the antibody indicated a non-competitive mechanism of inhibition , a valuable insight for therapeutic development.

• Clinical translation: The pSTAT3 whole blood assay has been successfully translated to clinical applications, monitoring receptor occupancy in healthy volunteers treated with ATR-107, where complete receptor occupancy was observed for up to 42 days post-dose . This demonstrates the value of pSTAT3 as a translational biomarker connecting preclinical and clinical stages of drug development.

These applications underscore how pSTAT3 monitoring not only supports dose selection and patient stratification but also provides fundamental insights into drug mechanisms of action, ultimately guiding therapeutic development strategies.

What strategies exist for distinguishing between specific STAT3 isoforms using antibodies?

Distinguishing between STAT3 isoforms, particularly STAT3α and STAT3β, requires specialized antibody approaches due to their high sequence homology. Effective strategies include:

• Targeting isoform-specific C-terminal sequences: The development of monoclonal antibodies that recognize unique C-terminal sequences has proven effective. For STAT3β, antibodies have been raised against the seven C-terminal amino acids (FIDAVWK) that are unique to this isoform and absent in STAT3α . This approach ensures specificity without cross-reactivity to the more abundant STAT3α isoform.

• Immunization strategy optimization: For generating isoform-specific antibodies, the choice of immunizing peptide is critical. In the case of STAT3β-specific antibodies, researchers have successfully used a 12-amino acid peptide (DEPKGFIDAVWK) that includes the seven unique C-terminal residues plus five additional amino acids to enhance immunogenicity .

• Rigorous validation: Multiple validation steps are essential to confirm isoform specificity:

  • ELISA testing against both free peptide and BSA-conjugated peptide immunogens

  • Western blotting comparison using cells expressing different STAT3 isoforms

  • Immunoprecipitation followed by mass spectrometry to confirm antibody selectivity

• Epitope mapping: Comprehensive understanding of antibody binding sites through techniques like steric competition studies helps ensure specificity and appropriate antibody selection for different applications .

When properly developed and validated, isoform-specific antibodies enable researchers to investigate the distinct biological roles of different STAT3 variants, which is particularly important given their potentially different functions in normal physiology and disease states.

How can competing epitope analysis enhance pSTAT3 antibody selection for complex experimental designs?

Competing epitope analysis represents a sophisticated approach to optimize antibody selection for complex experimental designs involving pSTAT3 detection. This methodology provides several advantages:

• Epitope mapping: Steric competition studies between different anti-pSTAT3 antibodies reveal their relative binding positions on the target protein. As illustrated in research on p53 antibodies, creating an epitope map through competition radioimmunοassays helps visualize the spatial relationship between different antibody binding sites . A similar approach can be applied to pSTAT3 antibodies.

• Compatible antibody pair identification: For techniques requiring multiple antibodies (such as sandwich ELISA or co-immunoprecipitation), epitope mapping identifies antibody pairs that bind to non-overlapping epitopes, ensuring they don't interfere with each other's binding . This can be visualized through epitope maps showing the degree of overlap between different antibodies.

• Functional domain targeting: Understanding which domain an antibody targets provides insights into its potential functional effects. For pSTAT3, antibodies targeting the SH2 domain, DNA-binding domain, or transactivation domain may have different utilities depending on the research question .

• Validation of complementary approaches: As demonstrated in p53 research, solid-phase radioimmunoassays using different antibody combinations can validate detection specificity and provide complementary approaches to study the same protein . When applied to pSTAT3, this approach can enhance detection reliability.

The table below represents a hypothetical example of how steric competition data might be organized for pSTAT3 antibodies, similar to the approach used for p53 antibodies in the research literature :

This approach enables researchers to strategically select antibody combinations that provide complementary information or enhance detection sensitivity in complex experimental designs.

How can researchers address common artifacts and pitfalls in pSTAT3 detection?

Researchers frequently encounter several artifacts and pitfalls when detecting pSTAT3. Addressing these challenges requires systematic troubleshooting approaches:

• Rapid dephosphorylation artifacts: STAT3 phosphorylation is highly dynamic and sensitive to phosphatase activity. To prevent dephosphorylation during sample processing:

  • Maintain samples at 4°C whenever possible

  • Include phosphatase inhibitors in all lysis buffers

  • Process samples rapidly, particularly for ex vivo analyses

  • Consider direct fixation of cells/tissues before processing when applicable

• Non-specific antibody binding: This common issue can be addressed through:

  • Careful antibody validation using appropriate positive and negative controls

  • Optimizing blocking conditions (5% non-fat milk powder has been shown effective for western blotting)

  • Including competition controls with phosphorylated peptides

  • Using phospho-specific and total STAT3 antibodies from different host species to avoid cross-reactivity in co-detection experiments

• Biological variability in baseline phosphorylation: Baseline pSTAT3 levels vary between donors and experimental conditions. This can be managed by:

  • Processing samples within a standardized timeframe (e.g., within 2 hours after blood collection)

  • Including unstimulated controls for each experimental subject

  • Normalizing phosphorylation signals to total STAT3 levels

  • Using fold-change calculations rather than absolute values when comparing across experiments

• Stimulus-dependent timing considerations: The kinetics of STAT3 phosphorylation vary depending on the stimulus. For example, IL-21 induces optimal STAT3 phosphorylation after 15 minutes of stimulation at 37°C . Researchers should perform time-course experiments to determine optimal timepoints for their specific experimental system and stimuli.

By systematically addressing these potential pitfalls, researchers can enhance the reliability and reproducibility of their pSTAT3 detection assays across different experimental platforms.

What are the optimal approaches for quantifying pSTAT3 levels across different experimental platforms?

Quantification of pSTAT3 levels requires platform-specific approaches to ensure accuracy and reproducibility:

• Western blotting quantification:

  • Always normalize pSTAT3 signal to total STAT3 expression in the same sample

  • Use digital imaging systems rather than film for linear dynamic range

  • Perform densitometry with appropriate software, ensuring signals fall within the linear range

  • Include a dilution series of a reference sample to confirm quantification linearity

  • Report results as fold-change relative to control conditions rather than absolute values

• Flow cytometry quantification:

  • Express results as median fluorescence intensity (MFI) rather than percent positive cells

  • Establish gates based on fluorescence-minus-one (FMO) controls

  • For inhibition studies, generate complete dose-response curves to determine IC50 values

  • Plot pSTAT3 levels (fluorescence intensity) against inhibitor concentrations to generate inhibition curves (e.g., IC50 of 1.45 ± 0.26 ng/ml for ATR-107)

  • Consider using calibration beads to normalize fluorescence units across experiments

• Imaging flow cytometry quantification:

  • Utilize nuclear translocation analysis wizards (e.g., in IDEAs software) to assess similarity scores

  • Calculate the correlation of pixel values between nuclear stain (DAPI) and pSTAT3 images on a per-cell basis

  • Segment analysis based on additional markers (e.g., CD4+ or CD19+ populations)

  • Report both intensity and localization metrics for comprehensive pathway analysis

• Solid-phase immunoassay quantification:

  • Establish standard curves using recombinant phosphorylated STAT3 protein

  • Ensure sample dilutions fall within the linear range of the standard curve

  • Titrate lysates over a wide range of dilutions (e.g., 10,000-fold) to determine optimal concentration for quantification

  • Plot cellular equivalents (e.g., from 2 × 103 to 2 × 107 cells) to standardize across experiments

Cross-platform validation, using at least two independent methods to quantify pSTAT3 in the same experimental system, significantly enhances confidence in the observed results and provides complementary insights into STAT3 signaling dynamics.

How can researchers validate the functional significance of observed changes in pSTAT3 levels?

Validating the functional significance of pSTAT3 changes requires connecting phosphorylation status to downstream biological outcomes through multiple complementary approaches:

• Correlation with nuclear translocation: Since STAT3 activation leads to nuclear translocation, researchers should confirm that changes in phosphorylation correlate with alterations in subcellular localization. Imaging flow cytometry provides a powerful tool for this purpose, enabling visualization of pSTAT3 nuclear accumulation following stimulation and its blockade by inhibitors . The co-localization of pSTAT3 (red) with nuclear staining (green) confirms functional activation beyond mere phosphorylation .

• Downstream gene expression analysis: Activated STAT3 regulates transcription of target genes involved in cell survival, proliferation, and other processes. Changes in pSTAT3 should be correlated with expression changes in these genes, which can be measured by:

  • Quantitative RT-PCR for selected STAT3 target genes

  • Chromatin immunoprecipitation (ChIP) to assess pSTAT3 binding to target promoters

  • RNA-seq to comprehensively profile transcriptional responses

• Functional bioassays: Biological outcomes dependent on STAT3 activation provide functional validation:

  • Proliferation assays (since STAT3 regulates cell proliferation)

  • Survival/apoptosis measurements

  • Cytokine production (relevant in immune cell studies)

  • Specific disease model outcomes (e.g., autoantibody production in autoimmune models)

• Receptor occupancy correlation: In pharmacological studies, the correlation between receptor occupancy and pSTAT3 inhibition provides mechanistic validation. For example, studies with ATR-107 demonstrated an excellent inverse correlation between inhibition of pSTAT3 signal and occupancy of IL-21R by the antibody in both T cells and B cells . This correlation confirms that reduced phosphorylation directly results from impaired receptor activation.

• Genetic validation approaches: Complementing pharmacological studies with genetic approaches strengthens functional validation:

  • STAT3 knockdown/knockout studies to confirm signal specificity

  • Phosphorylation site mutants (e.g., Y705F) to establish causality

  • Isoform-specific manipulations using STAT3β-specific antibodies

By integrating these multiple layers of validation, researchers can establish confident connections between observed changes in pSTAT3 levels and their biological significance in both physiological and pathological contexts.